IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
30th Lab in Thyrocare’s expanding network to bring advanced, affordable diagnostics in Bihar and beyond
This significant milestone enhances our global regulatory standing
The FDA issued Form 483 with one observation related to building and facility management
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
The Subsidiary has received one inspectional observation in Form 483
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Subscribe To Our Newsletter & Stay Updated
